HIFU FOR
UTERINE FIBROIDS
HIFU destroys symptomatic uterine fibroids without surgery — using focused ultrasound to coagulate fibroid tissue while leaving the uterus intact, healthy tissue undamaged, and the patient walking out of the treatment suite the same day.
analyticsAt a Glance
- check_circleNo surgery, no incisions, no general anaesthesia — same-day outpatient treatment
- check_circleMRgFUS (ExAblate) and USgHIFU (HAIFU) are both approved and widely performed — suited to different fibroid types
- check_circleSymptom relief in 70–90% of patients; fibroid volume reduction of 40–70% at 6 months
- check_circleUterus-preserving — fertility can be maintained; no hormonal side effects from the procedure itself
Why HIFU Has Transformed Fibroid Treatment
Uterine fibroids affect up to 70% of women by age 50. Traditional treatment options — hysterectomy, myomectomy, or uterine artery embolisation — all involve surgery or invasive catheterisation with associated recovery, risk, and in the case of hysterectomy, permanent loss of the uterus. HIFU changed this equation fundamentally: it is the first treatment that can destroy a fibroid without entering the body at all.
“For a woman who needs her fibroid treated but wants to preserve her uterus, avoid surgery, and return to work the next day — HIFU is the option that previously did not exist.”
MRgFUS: Precision in the MRI Scanner
The ExAblate system integrates a focused ultrasound transducer into an MRI table. The patient lies prone with the transducer coupled to the skin below the lower abdomen. Real-time MR thermometry maps the temperature at every focal point — confirming that fibroid tissue is being ablated to target temperature while bowel and sacrum stay cool. FDA and CE approved.
USgHIFU: High-Volume Treatment in China
Chinese-manufactured systems — primarily the HAIFU (Chongqing HAIFU Medical Technology) — use diagnostic ultrasound for real-time guidance. The patient sits in a water bath with the transducer positioned below. Without the MRI constraint, treatment positions and fibroid geometries that are challenging for MRgFUS can often be treated. Hundreds of thousands of procedures have been performed in China.
Key Clinical Outcomes
Published data from pivotal trials and large clinical series document the following outcomes for HIFU fibroid treatment.
- 70–90%Symptom relief rate at 6–12 monthsReported across MRgFUS and USgHIFU series — including reduction in heavy bleeding, pelvic pressure, and pain scores.
- 40–70%Fibroid volume reduction at 6 monthsPercentage reduction in fibroid volume on follow-up MRI — degree of reduction correlates with non-perfused volume (NPV) achieved at treatment.
- <1%Major complication rateHIFU for fibroids has an excellent safety profile — major complications including skin burns, bowel injury, or nerve injury are reported in <1% of cases at experienced centres.
- Same dayTypical discharge timingMost patients are discharged 1–4 hours after the procedure ends. Return to normal light activity within 24–48 hours for the majority.
What Happens During HIFU Fibroid Treatment
The treatment session varies between MRgFUS and USgHIFU systems but follows a consistent pathway from preparation to discharge.
- 1
Pre-Treatment Preparation
Abdominal skin is shaved and treated with a depilatory cream 24 hours before the procedure to prevent acoustic interference from hair. A strict bowel preparation (clear fluids, laxatives) empties the bowel to clear the acoustic path to the uterus. A urinary catheter is placed on arrival to allow bladder filling during treatment — a full bladder displaces bowel loops away from the acoustic path.
- 2
Positioning and Coupling
For MRgFUS: the patient lies prone on the MRI table with the gel-coupled transducer pressed against the lower abdomen. For USgHIFU: the patient sits or lies in a water bath, with the transducer positioned below the water surface at the uterine level.
- 3
Imaging and Planning
Pre-treatment MRI (MRgFUS) or ultrasound (USgHIFU) maps the fibroid dimensions, marks the treatment volume, and identifies any bowel loops, bladder, or sacral structures that must be avoided in the acoustic path.
- 4
HIFU Ablation
Sequential focal points are delivered across the fibroid in a systematic grid pattern. For MRgFUS, real-time thermometry confirms target temperature at each point. For USgHIFU, the operator monitors tissue echogenicity changes as a proxy for thermal effect. Patients are awake and report any unusual pain or sensation.
- 5
Post-Treatment Imaging
Contrast-enhanced MRI (MRgFUS) or contrast ultrasound confirms the non-perfused volume — the proportion of fibroid tissue that no longer enhances, indicating successful ablation. NPV >80% is the technical success target at most centres.
- 6
Recovery and Discharge
Catheter removal, light snack, and 1–2 hours of monitoring. Mild pelvic cramping for 24–48 hours is expected. Patients are discharged on oral analgesics and typically return to work within 1–3 days.
Eligibility Criteria for HIFU Fibroid Treatment
HIFU fibroid treatment is most effective when the following criteria are met. Borderline cases should be reviewed by a specialist with experience in HIFU fibroid selection.
| Criterion | Optimal for HIFU | Less Suitable / Caution |
|---|---|---|
| Fibroid type | Intramural or subserosal fibroids | Submucosal fibroids — hysteroscopic resection preferred; pedunculated fibroids — stalk vascularity may persist |
| Fibroid size | 3–10 cm (single dominant fibroid ideal) | >10 cm — very long treatment time; multiple large fibroids — session may be insufficient |
| MRI signal on T2 | Hypointense (dark) fibroids — respond best | Hyperintense (bright/cellular) fibroids — less responsive, more vascularity, higher recurrence |
| Anterior wall position | Fibroid in anterior or central uterus | Posterior fibroid with sacrum <4 cm from fibroid — sacral nerve injury risk; requires skilled operator |
| Distance from serosa | >1 cm from uterine serosa preferred | <1 cm — risk of thermal injury to adjacent structures |
| Prior uterine surgery | No prior surgery preferred | Prior caesarean section — scar tissue may distort acoustic path and tissue response |
| Desire for pregnancy | Uterus-preserving — fertility maintained | If active pregnancy planning: discuss with MFM specialist — limited but reassuring fertility data exist |
MRgFUS vs USgHIFU: Which Is Right for You?
Both systems achieve excellent fibroid treatment outcomes — but they differ in patient positioning, monitoring precision, geographic availability, and cost.
MRgFUS (ExAblate)
- Real-time MR thermometryTemperature maps the entire focal zone in real time — the gold standard for confirming target temperature and protecting adjacent structures.
- FDA and CE approvedStrongest regulatory endorsement — relevant for patients or insurers requiring regulatory-approved treatment documentation.
- Better for anterior fibroids with MRI-compatible anatomyOptimal for hypointense, anterior/central intramural fibroids ≤10 cm with no bowel in the acoustic path.
- Higher equipment costMRgFUS requires an MRI scanner and specialised integration — capital cost significantly higher than USgHIFU; typically fewer centres.
USgHIFU (HAIFU)
- No MRI claustrophobia constraintOpen treatment couch and water bath — more accessible and comfortable for patients who cannot tolerate prolonged MRI bore confinement.
- Wider availability in ChinaHAIFU and similar Chinese systems are installed at 200+ centres across China — more treatment options and shorter waiting times for international patients.
- Lower costWithout the MRI infrastructure requirement, USgHIFU treatment costs are significantly lower — relevant for self-funding international patients.
- Can treat some MRgFUS-ineligible patientsPatient size, positioning limitations, or fibroid geometry may preclude MRgFUS but still allow USgHIFU treatment.
More from the HIFU Therapy Resource Library
Continue exploring HIFU — from the physics to prostate, liver, and bone applications.
- HIFU Therapy — Complete Treatment Guide
- What Is HIFU? Non-Invasive Focused Ultrasound Explained
- HIFU Physics: How Acoustic Focusing Destroys Tissue
- HIFU for Prostate Cancer: Whole-Gland and Focal Treatment
- HIFU for Liver Cancer: HCC and Liver Metastases
- HIFU for Bone Metastases: Pain Palliation and Local Control
Frequently Asked Questions
Common questions from women considering HIFU for uterine fibroid treatment.
About HIFU Fibroid Treatment
Can I still get pregnant after HIFU fibroid treatment?
Yes — HIFU preserves the uterus entirely, and pregnancies have been reported after both MRgFUS and USgHIFU fibroid treatment. The published pregnancy data are reassuring — large Chinese HAIFU series report successful pregnancies with no significant increase in miscarriage, preterm birth, or caesarean section rates compared to the general population. MRgFUS fertility data from the ExAblate pivotal studies are more limited in number but similarly reassuring. If fertility preservation is a primary goal, discuss HIFU specifically as a fertility-preserving option with a maternal-foetal medicine specialist before proceeding.
How long does the symptom relief last after HIFU?
Most patients experience sustained symptom relief for 2–3 years after HIFU fibroid treatment. The treated fibroid volume continues to reduce over 6–12 months post-procedure. Fibroids can recur from untreated smaller fibroids or new fibroid growth — the 5-year re-intervention rate for HIFU is approximately 20–30%, compared to 15–20% for uterine artery embolisation and near zero for hysterectomy (which removes the uterus entirely). For women who want to avoid surgery and are prepared to consider re-treatment if symptoms recur, HIFU remains an excellent first intervention.
What is the cost of HIFU fibroid treatment in China?
HIFU fibroid treatment at Chinese centres typically costs USD 2,500–5,000 for a single session — significantly below the USD 8,000–20,000 range at MRgFUS centres in the United States or Western Europe. Chinese USgHIFU centres (HAIFU) account for most of this cost advantage. The total trip cost for an international patient — including flights, accommodation, and procedure — typically ranges from USD 4,000–8,000 depending on origin. CancerFax can provide an itemised estimate based on your specific fibroid characteristics and preferred system type.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Considering HIFU for Your Uterine Fibroid?
CancerFax coordinates access to specialist HIFU fibroid centres in China — where both MRgFUS and USgHIFU are routinely performed, with costs significantly below Western equivalents and same-day treatment available for eligible patients.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist or gynaecologist before making treatment decisions.